Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 20, 2001

View Archived Issues

European MAA submitted for Onzar in the treatment of cutaneous T-cell lymphoma

BMS submits NDA for Vanlev for the treatment of hypertension

Cangene seeks approval for antihepatitis B hyperimmune in Canada

FDA completes IND review of candidate anti-HIV drug TMC-125

Boehringer Ingelheim submits U.S. NDA for Spiriva in chronic obstructive pulmonary disease

Progen receives funding for malaria vaccine projects

Initiation of phase II trial of Ceplene in triple-drug combination therapy

Activax vaccine component enters clinical testing for prevention of travelers' diseases

Patient enrollment completed for phase III trial of Neovastat in renal cell carcinoma

Novartis Ophthalmics and Kissei enter license option agreement for novel glaucoma agent

Encouraging oral insulin results obtained with BioSante's CAP delivery system

Boehringer Ingelheim and Structural Bioinformatics jointly research HIV protein targets

TMC-114: preclinical and early clinical results discussed at ICAAC

Broad-spectrum antiherpesvirus agents presented by Pharmacia in Chicago

DNA-interacting compounds under development at GeneSoft as antibacterial agents

ICAAC news: more on efflux pump inhibitors in development at Essential Therapeutics and Daiichi

Data presented at this year's ICAAC meeting support continued development of anidulafungin

Bay-41-4109 characterized at ICAAC as a novel, promising anti-HBV agent

Update on clinical status of E-7070

Clinical-stage heart failure therapeutic available for licensing from Banyu

Urokinase inhibitors identified by Abbott as antiangiogenic agents

Abbott researchers present benzonitrile-based protein farnesyltransferase inhibitors

Potential new therapeutic agents for BPH in development at Merck

Indian researchers discover antimalarial compounds

NMDA receptor antagonists and their use disclosed by Roche

Promoters of fibrinolysis designed at Torii as new antithrombotic drugs

Japanese companies decide not to seek approval in Japan for clinprost

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.